Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma-Reference-Cited by-同舟云学术

Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma

Published:2019-12-10 Issue:1 Volume:80 Page:1-7
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hanna Kirollos S.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01241-7.pdf

Reference28 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

2. NCCN. The NCCN Clinical Practical Guidelines in Oncology Bladder Cancer (Version 3.2019). 2019; http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed 30 July 2019.

3. National Cancer Institute. SEER stat fact sheets: Bladder cancer. 2019. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 30 July 2019.

4. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.

5. Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products; April 2019.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2;Oncogenesis;2023-10-02

2. Optimizing the safety of antibody–drug conjugates for patients with solid tumours;Nature Reviews Clinical Oncology;2023-06-09

3. Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors;Frontiers in Immunology;2022-11-21

4. Nectin-4 is widely expressed in head and neck squamous cell carcinoma;Oncotarget;2022-10-20

5. Selective Delivery of Clinically Approved Tubulin Binding Agents through Covalent Conjugation to an Active Targeting Moiety;Current Medicinal Chemistry;2022-09